skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
abstract
Highlights
- •Farletuzumab (FAR), a monoclonal antibody to folate receptor alpha, which is expressed in epithelial ovarian cancer (EOC).
- •FAR has shown activity against EOC in platinum-sensitive relapse when combined with carboplatin and a taxane.
- •Carboplatin in combination with pegylated liposomal doxorubicin (PLD) is a frequently used alterative regimen.
- •This safety study assessed the addition of FAR to carboplatin/PLD, with a view toward future larger studies.
- •This combination was generally well tolerated; adverse event profile was similar to that of carboplatin/PLD alone.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.